human normal immunoglobulin: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
human normal immunoglobulin: clinical details
Prescribing considerations
- Confirm the product and route are licensed for the intended indication; indications are not interchangeable across brands.
- Assess previous immunoglobulin reactions, IgA deficiency with anti-IgA antibodies, renal and thrombotic risk, hydration status and active infection.
- Initiate and monitor treatment through a clinician experienced in immunodeficiency or the relevant immunomodulatory indication.
- Record product name and batch number for every administration.
- Review vaccine plans and potential interference with serological testing.
Contraindications and cautions
- Hypersensitivity to human immunoglobulin or a product excipient.
- Selected intravenous products: selective IgA deficiency with anti-IgA antibodies because of anaphylaxis risk.
- All selected subcutaneous products must not be administered intravascularly.
- Hizentra: hyperprolinaemia type I or II.
- Subgam and Cutaquig must not be given intramuscularly in severe thrombocytopenia or other haemostatic disorders.
Monitoring
- Observe during administration and after treatment according to product-specific precautions, with enhanced observation after first exposure, switching products or a prolonged treatment gap.
- Assess clinical infection burden and serum IgG concentrations during replacement therapy.
- For intravenous treatment, consider hydration, urine output and renal function; monitor patients at risk of thrombosis, haemolysis or fluid-related complications.
- Investigate compatible symptoms for haemolysis, thrombosis, kidney injury, aseptic meningitis or lung injury.
- Use glucose-specific monitoring systems with Cutaquig where blood-glucose testing is required.
Clinical pharmacology
Human normal immunoglobulin supplies polyclonal IgG antibodies representative of the donor population. Intravenous administration provides immediate systemic bioavailability, while subcutaneous administration gives slower absorption and steadier exposure. Its immunomodulatory effects involve several overlapping antibody- and immune-cell pathways.
Formulation and product differences
- Yimmugo and Gamunex are intravenous solutions; Hizentra, Subgam and Cutaquig are subcutaneous preparations.
- Products differ in concentration, IgA content, excipients, storage, presentation and infusion-device compatibility and should not be substituted without clinical and pharmacy review.
- Hizentra contains L-proline; Cutaquig contains maltose; Subgam contains sodium and polysorbate 80; Yimmugo contains polysorbate 80; Gamunex contains glycine.
- Cutaquig maltose can interfere with some glucose meters. Gamunex has product-specific restrictions concerning dilution and heparin in a shared lumen.
human normal immunoglobulin preparations and strengths
Solution for infusion
Route: Intravenous
Strengths: 100 mg/mL, 10 g, 5% w/v, 10%
Injection
Route: Parenteral
Strengths: 165 mg/mL, 200 mg/mL
human normal immunoglobulin interactions
Tell the immunoglobulin team about medicines, vaccines and planned laboratory tests.
Live attenuated vaccines, including measles, mumps, rubella and varicella vaccines
Transferred antibodies can reduce vaccine response, so vaccination timing must be checked with the immunisation or specialist team.
Loop diuretics
Selected intravenous product information advises avoiding concurrent use because of renal-safety concerns.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.